UNITED GUARDIAN INC UG
United-Guardian, Inc. ("Company") is a Delaware corporation that, through its Guardian Laboratories division, manufactures, markets and develops specialty cosmetic, personal care and sexual wellness ingredients and a line of healthcare products including pharmaceuticals and medical lubricants. We conduct various research and development ("R&D") activities. Our R&D department primarily develops new and unique specialty cosmetic and sexual wellness ingredients. We develop new products using natural and environmentally friendly raw materials, which is a priority for many of our cosmetic customers. The R&D department also modifies, refines, and expands the uses for existing products, with the goal of further developing the markets that our products are used in. All the products that we market, except for Renacidin®, are produced at our facility in Hauppauge, New York. Renacidin, a urological product, is manufactured for us by an outside contract manufacturer.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.5M | $12.2M | $10.9M | $12.7M | $13.9M | $11.0M | $13.6K | $13.4M | $13.0M | $10.8M |
| Cost of revenue | $5.4M | $5.7M | $5.5M | $6.0M | $5.7M | $4.9M | $5.7M | $5.3M | $5.3M | $4.9M |
| Gross profit | $5.1M | $6.5M | $5.4M | $6.7M | $8.2M | $6.1M | -$5.6M | $8.1M | $7.7M | $5.9M |
| R&D | $463.6K | $456.8K | $464.0K | $490.8K | $478.6K | $451.2K | $397.4K | $399.5K | $646.1K | $651.8K |
| Total operating expenses | $8.3M | $8.5M | $8.0M | $8.7M | $8.3M | $7.3M | $8.2M | $7.9M | $1.8M | $1.9M |
| Operating income | $2.2M | $3.6M | $2.9M | $4.0M | $5.7M | $3.6M | $5.4M | $5.6M | $5.2M | $3.4M |
| Pre-tax income | $2.6M | $4.1M | $3.3M | $3.2M | $5.9M | $4.2M | $6.0M | $5.5M | $5.6M | $3.7M |
| Income tax | $537.3K | $857.6K | $669.4K | $658.2K | $1.2M | $856.0K | $1.3M | $1.1M | $1.7M | $1.1M |
| Net income | $2.1M | $3.3M | $2.6M | $2.6M | $4.7M | $3.3M | $4.8M | $4.4M | $3.8M | $2.6M |
| EPS, basic | 0.46 | 0.71 | 0.56 | 0.56 | 1.01 | — | — | — | — | — |
| EPS, diluted | — | — | — | — | 1.01 | 0.72 | 1.04 | 0.95 | 0.84 | 0.56 |
| Shares, diluted (wtd. avg.) | $4.6M | $4.6M | $4.6M | $4.6M | $4.6M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.3M | $1.9M | $8.2M | $830.5K | $531.2K | $591.4K | $1.0M | $550.1K | $724.7K | $424.3K |
| Short-term investments | $7.3M | $7.5M | $851.3K | $5.7M | $7.6M | $7.6M | $6.9M | $7.6M | $7.7M | — |
| Receivables | $1.6M | $1.4M | $1.6M | $1.4M | $1.8M | $1.4M | $2.1M | $1.7M | $1.9M | $1.6M |
| Inventory | $1.5M | $1.5M | $1.2M | $1.7M | $1.4M | $1.4M | $1.2M | $1.5M | $1.3M | $1.3M |
| Total current assets | $12.2M | $12.7M | $12.3M | $10.0M | $11.6M | $11.2M | $11.6M | $11.7M | $11.9M | $13.7M |
| Property, plant and equipment | $907.2K | $956.4K | $619.2K | $559.2K | $658.9K | $673.7K | $780.7K | $827.9K | $942.9K | $1.1M |
| Total assets | $13.1M | $13.8M | $12.9M | $10.6M | $12.2M | $11.9M | $12.4M | $12.5M | $12.9M | $14.9M |
| Accounts payable | $480.8K | $425.0K | $134.4K | $30.4K | $410.9K | $31.8K | $71.4K | $186.8K | $354.3K | $82.8K |
| Total current liabilities | $1.7M | $1.9M | $1.5M | $1.4M | $2.3M | $1.4M | $1.3M | $1.4M | $1.4M | $1.0M |
| Total liabilities | $1.9M | $1.9M | $1.5M | — | — | — | — | — | — | — |
| Retained earnings | $10.8M | $11.4M | $10.9M | $8.8M | $9.4M | $9.9M | $10.2M | $10.5M | $10.5M | $13.2M |
| Total equity | $11.2M | $11.9M | $11.4M | $9.3M | $9.8M | $10.4M | $10.6M | $10.9M | $11.4M | $13.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.0M | $3.5M | $3.1M | $2.5M | $5.3M | $3.6M | $4.5M | $5.0M | $4.0M | $2.3M |
| Depreciation and amortisation | $108.2K | $95.9K | $105.7K | $135.4K | $146.0K | $165.3K | $175.8K | $191.9K | $200.7K | $187.0K |
| Capital expenditure | $59.0K | $433.1K | $165.7K | $75.2K | $116.4K | $43.4K | $113.8K | $75.0K | $38.1K | $166.7K |
| Investing cash flow | $175.3K | -$7.1M | $4.7M | $897.6K | -$183.5K | -$468.7K | $1.1M | -$308.8K | $2.8M | $490.2K |
| Financing cash flow | -$2.8M | -$2.8M | -$459.4K | -$3.1M | -$5.2M | -$3.6M | -$5.0M | -$4.8M | -$6.5M | -$3.4M |
| Dividends paid | $2.8M | $2.8M | $459.4K | $3.1M | $5.2M | $3.6M | $5.0M | $4.8M | $6.5M | $3.4M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001171843-26-002251.
Others in SIC 2844
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| CL | COLGATE PALMOLIVE CO | $70.77B | 33.8x | 1.4% |
| EL | ESTEE LAUDER COMPANIES INC | $37.63B | 207.7x | 5.0% |
| KVUE | Kenvue Inc. | $36.00B | 24.7x | -2.1% |
| ELF | e.l.f. Beauty, Inc. | $6.47B | 249.2x | 24.6% |
| IPAR | INTERPARFUMS INC | $3.74B | 22.3x | 2.5% |
| COTY | COTY INC. | $2.58B | — | -1.5% |
| EPC | EDGEWELL PERSONAL CARE Co | $1.33B | 54.5x | -1.3% |
| WALD | Waldencast plc | $156.3M | — | -0.7% |